FRIENDSWOOD, Texas, June 16, 2026
Castle Biosciences has announced that its TissueCypher® Barrett’s Esophagus Test has surpassed 100,000 clinical test orders, marking a significant milestone for one of the most widely adopted precision medicine tools designed to assess cancer progression risk in patients with Barrett’s esophagus (BE). The AI-derived diagnostic test provides clinicians with a personalized five-year risk assessment for progression to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC), a highly aggressive form of gastrointestinal cancer associated with poor survival outcomes. The achievement underscores the growing role of advanced molecular diagnostics and artificial intelligence in guiding individualized patient management strategies and improving decision-making in gastroenterology practice.
AI-Powered Precision Medicine Enhances Barrett’s Esophagus Management
Barrett’s esophagus remains the only recognized precursor to esophageal adenocarcinoma, making accurate risk assessment essential for identifying patients who may benefit from intensified surveillance or early intervention. Traditional histopathological evaluation has long served as the foundation of Barrett’s esophagus management; however, accurately predicting which patients are most likely to progress to cancer remains a significant clinical challenge. TissueCypher® utilizes an advanced AI-derived spatialomics platform that analyzes molecular and tissue-based biomarkers from standard esophageal biopsy samples to generate an individualized risk score.
By identifying biological changes that may occur before visible dysplasia develops, the test helps physicians stratify patients into low-, intermediate-, and high-risk categories. This personalized approach allows healthcare providers to tailor surveillance intervals and consider endoscopic eradication therapies for patients with elevated risk while potentially reducing unnecessary procedures for lower-risk individuals. The growing adoption of TissueCypher reflects increasing demand for precision medicine solutions capable of supporting evidence-based clinical decisions.
Extensive Clinical Validation Supports Growing Adoption
Advertisement
The TissueCypher platform has been extensively studied and validated across a large body of clinical evidence. According to Castle Biosciences, the test has been evaluated using biopsy samples from more than 8,000 patients and supported by over 17 peer-reviewed scientific publications. Research findings have consistently demonstrated that TissueCypher serves as a strong independent predictor of disease progression when compared with conventional histopathological assessment alone. The technology is indicated for patients with non-dysplastic Barrett’s esophagus, indefinite for dysplasia, and low-grade dysplasia, providing clinicians with additional information beyond standard pathology reports.
Because the assay is performed using routine esophageal pinch biopsy samples collected during standard endoscopic procedures, integration into existing clinical workflows requires no additional invasive interventions. The milestone of surpassing 100,000 orders highlights growing confidence among gastroenterologists and healthcare systems in the clinical utility of molecular risk stratification tools as part of modern Barrett’s esophagus management.
Precision Diagnostics Driving Earlier Cancer Risk Identification
The increasing use of AI-enabled diagnostics reflects a broader shift toward precision medicine across oncology and gastroenterology. TissueCypher’s ability to detect molecular signatures associated with future progression to high-grade dysplasia and esophageal adenocarcinoma provides clinicians with actionable information that may support earlier intervention and improved patient outcomes. For many patients diagnosed with Barrett’s esophagus, understanding individualized cancer risk can also reduce uncertainty and support informed treatment planning.
As healthcare providers continue adopting data-driven approaches to cancer prevention and surveillance, technologies such as TissueCypher are expected to play an increasingly important role in identifying patients who require closer monitoring while helping optimize healthcare resources. With more than 100,000 clinical orders now completed, Castle Biosciences has established TissueCypher as a leading example of how artificial intelligence, molecular pathology, and precision diagnostics are transforming the management of gastrointestinal diseases and advancing personalized cancer risk assessment.
Source: Castle Biosciences press release
